Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
dc.contributor.author | Roberts, C | |
dc.contributor.author | Strauss, VY | |
dc.contributor.author | Kopijasz, S | |
dc.contributor.author | Gourley, C | |
dc.contributor.author | Hall, M | |
dc.contributor.author | Montes, A | |
dc.contributor.author | Abraham, J | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Kennedy, R | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Folkes, LK | |
dc.contributor.author | Stratford, M | |
dc.contributor.author | Nicum, S | |
dc.date.accessioned | 2020-01-29T15:17:47Z | |
dc.date.available | 2020-01-29T15:17:47Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, et al. Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. Br J Cancer. 2019:10. | en |
dc.identifier.pmid | 31813938 | en |
dc.identifier.doi | 10.1038/s41416-019-0674-4 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622661 | |
dc.description.abstract | BACKGROUND: Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AG014699, even after these cells acquired resistance to a PARP inhibitor or cisplatin. METHODS: This phase II single-arm trial investigated the activity of 6MP 55-75?mg/m2 per day, and methotrexate 15-20?mg/m2 per week in advanced breast or platinum-resistant ovarian cancer patients with a BRCA1/2 germline mutation, who had progressed after?³1 previous line of chemotherapy. The primary outcome was objective response including stable disease (SD) as an assessment of clinical benefit rate (CBR), at 8 weeks, by RECIST v1.1. Secondary outcomes included overall survival (OS) and progression-free survival (PFS). RESULTS: In total, 67 evaluable patients were recruited; 55 ovarian and 11 breast cancer patients. In total, 21 patients had SD (31%), one had a partial response (1.5%); CBR was 33% at 8 weeks. In total, 12/67 patients (18%) had SD at 16 weeks. In total, five ovarian cancer patients had SD for over 200 days. Median OS was 10.3 months (95% CI 6.9-14.5), median PFS 1.9 months (1.7-2.8). CONCLUSIONS: The overall activity of 6MP and methotrexate in these patients was low; however, there was a small group of patients who appeared to derive longer-term clinical benefit. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1038/s41416-019-0674-4 | en |
dc.title | Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours | en |
dc.type | Article | en |
dc.contributor.department | Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK | en |
dc.identifier.journal | British Journal of Cancer | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-02-03T15:14:29Z |